Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Left Ventricular Ejection Time Clear all
Completed Phase 3 Interventional Results available

DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY

NCT03571672
View directory record Official record
Conditions
Cardiac Disease
Interventions
DEFINITY
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Tucson, Arizona • San Diego, California • Wilmington, Delaware + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Nov 14, 2026, 1:34 PM EST
Terminated Not applicable Interventional

Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension

NCT00980031
View directory record Official record
Conditions
Myocardial Remodeling
Interventions
Eplerenone, Lactose Tablet
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 28, 2014 · Synced Nov 14, 2026, 1:34 PM EST
Terminated Phase 2 Interventional Results available

The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

NCT01887353
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jul 20, 2015 · Synced Nov 14, 2026, 1:34 PM EST
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

NCT02678312
View directory record Official record
Conditions
Pediatric Heart Failure
Interventions
LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
25
States / cities
Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Nov 14, 2026, 1:34 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

US Benchmarking Clinical Study

NCT07215715
View directory record Official record
Conditions
HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy, Cardiac Amyloidosis
Interventions
Not listed
Lead sponsor
eMyosound SAS
Industry
Eligibility
60 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 14, 2026, 1:34 PM EST
Recruiting Phase 2 Interventional

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

NCT06979362
View directory record Official record
Conditions
Heart Failure
Interventions
CDR132L, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
40 Years to 84 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
29
States / cities
Birmingham, Alabama • Tucson, Arizona • Covina, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 14, 2026, 1:34 PM EST
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

NCT04986202
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
AZD4831, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
21
States / cities
Alexander City, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Nov 14, 2026, 1:34 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Kosmos PLAX EF Pivotal Study

NCT07771231
View directory record Official record
Conditions
Heart, Heart Failure, Ejection Fraction, Left Ventricular Ejection Fraction, Left Ventricular Ejection Fraction Less Then or Equal to 50percent
Interventions
PLAX EF Manual vs. Automatic Measurement
Device
Lead sponsor
EchoNous Inc.
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Nov 14, 2026, 1:34 PM EST
Withdrawn No phase listed Observational

Left Ventricular Volume and Ejection Fraction: Validation of Real Time 3 Dimensional Transesophageal Echocardiography

NCT01734174
View directory record Official record
Conditions
3D Transesophageal and Transthoracic Echocardiogram
Interventions
transesophageal echocardiography (TEE), thermodilution, transthoracic echocardiography (TTE)
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Nov 14, 2026, 1:34 PM EST
Terminated Phase 4 Interventional Results available

Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan

NCT00840463
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions
Ambrisentan, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Nov 14, 2026, 1:34 PM EST
Recruiting Early Phase 1 Interventional

Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes

NCT06108076
View directory record Official record
Conditions
Type 2 Diabetes, Heart Failure, Reduced Ejection Fraction
Interventions
Ketone Monoester (KE)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Nov 14, 2026, 1:34 PM EST
Completed No phase listed Observational

Left Ventricular Torsional Hysteresis: A Global Parameter for Diastolic Function

NCT01431027
View directory record Official record
Conditions
Heart Failure, Diastolic Heart Failure, Heart Failure With Normal Ejection Fraction
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Nov 14, 2026, 1:34 PM EST
Completed Phase 4 Interventional Results available

HF Patients With LVADs Being Treated With SGLT2i

NCT05278962
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
SGLT2i, No SGLT2i
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Nov 14, 2026, 1:34 PM EST
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Novel On-body Evaluation of Cardiac Health for Oncology

NCT07158450
View directory record Official record
Conditions
Cardiotoxicity, Heart Failure
Interventions
Not listed
Lead sponsor
Skribe Medical
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
11
States / cities
Golden, Colorado • Littleton, Colorado • Clearwater, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 14, 2026, 1:34 PM EST
Completed No phase listed Observational

Restore EF Observational Study

NCT04648306
View directory record Official record
Conditions
Coronary Artery Disease, Unstable Angina, Angina, Stable, NSTEMI - Non-ST Segment Elevation MI
Interventions
Prophylactic Impella support for a non-emergent PCI
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Nov 14, 2026, 1:34 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Low Ejection Fraction in Single Lead ECG- Ochsner

NCT05010642
View directory record Official record
Conditions
Left Ventricular Dysfunction, Ventricular Dysfunction, Heart Diseases, Cardiovascular Diseases
Interventions
Use of Eko DUO electronic Stethoscope
Device
Lead sponsor
Eko Devices, Inc.
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Nov 14, 2026, 1:34 PM EST
Completed Phase 3 Interventional Results available

DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY

NCT03719612
View directory record Official record
Conditions
Cardiac Disease
Interventions
DEFINITY®
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Nov 14, 2026, 1:34 PM EST
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

NCT01300013
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Omecamtiv mecarbil
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Mobile, Alabama • Inglewood, California • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Nov 14, 2026, 1:34 PM EST
Completed Not applicable Interventional

Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)

NCT01900600
View directory record Official record
Conditions
Prior Acute Myocardial Infarction, Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l), Reduced Left Ventricle Ejection Fraction (<50%), Symptoms of Heart Failure (NYHA Class II-III)
Interventions
Cardiopulmonary exercise test, Echocardiogram
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 110 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Nov 14, 2026, 1:34 PM EST
Completed Not applicable Interventional Results available

Optimize RV Follow-up Selective Site Pacing Clinical Trial

NCT00949715
View directory record Official record
Conditions
Cardiac Pacing, Right Ventricular Pacing, Left Ventricular Ejection Fraction
Interventions
Medtronic or Vitatron Dual-Chamber Pacemaker, Medtronic SelectSecure 3830 Lead
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Des Moines, Iowa • Silver Spring, Maryland • Southfield, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Nov 14, 2026, 1:34 PM EST
Completed Phase 2 Interventional Results available

Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)

NCT00684021
View directory record Official record
Conditions
Left Ventricular Dysfunction
Interventions
Adult stem cells, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Nov 14, 2026, 1:34 PM EST
Withdrawn Not applicable Interventional

The Effects of Active VItamin D on Left Atrial Volume Index

NCT01630408
View directory record Official record
Conditions
Heart Failure
Interventions
Paricalcitol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Nov 14, 2026, 1:34 PM EST
Completed Phase 2 Interventional Results available

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

NCT03541603
View directory record Official record
Conditions
Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
Interventions
Levosimendan, Matching Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Nov 14, 2026, 1:34 PM EST
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

NCT04435626
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone (BAY94-8862), Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
6,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
107
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Nov 14, 2026, 1:34 PM EST